Stomach (Gastric) Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000315400-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Stomach (Gastric) Cancer Screening
Cancell/Cantron/Protocel (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions to Ask Your Health Care Provider About CAM
When considering complementary and alternative therapies, patients should ask their health care provider the following questions: What side effects can be expected?What are the risks associated with this therapy?Do the known benefits outweigh the risks?What benefits can be expected from this therapy?Will the therapy interfere with conventional treatment?Is this therapy part of a clinical trial?If so, who is sponsoring the trial?Will the therapy be covered by health insurance?
Lip and Oral Cavity Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview
There are different types of treatment for patients with lip and oral cavity cancer. Different types of treatment are available for patients with lip and oral cavity cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment. Patients with lip and oral cavity cancer should have their treatment planned by a team of doctors who are expert in treating head and neck cancer.Treatment will be overseen by a medical oncologist, a doctor who specializes in treating people with cancer. Because the lips and oral
Parathyroid Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Extrahepatic Bile Duct Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Unresectable, Recurrent, or Metastatic Extrahepatic Bile Duct Cancer
Patients with unresectable extrahepatic bile duct cancer have cancer that cannot be completely removed by the surgeon. These patients represent the majority of cases of bile duct cancer. Often a proximal bile duct cancer invades directly into the adjacent liver or into the hepatic artery or portal vein. Portal hypertension may result. Spread to distant parts of the body is uncommon, though transperitoneal and hematogenous hepatic metastases do occur with bile duct cancers of all sites. Invasion along the biliary tree and into the liver is common. Moreover, the majority of patients who undergo resection will develop recurrent disease within the hepatobiliary system or less frequently at distant sites.Patients with unresectable, recurrent, or metastatic extrahepatic bile duct cancer should be considered for inclusion in clinical trials whenever possible. Information about ongoing clinical trials is available from the NCI Web site.Treatment options:Relief of biliary obstruction is
Renal Cell Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (08 / 02 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Stage IV and Recurrent Renal Cell Cancer Added Motzer et al. as reference 30. Revised text to state that the primary endpoint was progression-free survival (PFS), and the data were analyzed when disease in 88% of the axitinib patients and 90% of the sorafenib patients had progressed, while 58% and 59%, respectively, had died.Revised text to state that median PFS was 8.3 months for axitinib and 5.7 months for sorafenib, and median overall survival (OS) was 20.1 months with axitinib versus 19.2 months with sorafenib; however, the largest benefit was seen in patients who received cytokines as first-line therapy and whose median PFS was 12.2 months with axitinib compared with 8.2 months with sorafenib, while median overall survival was 29.4 months with axitinib compared with 27.8 months with
Milk Thistle (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Overview
This complementary and alternative medicine (CAM) information summary provides an overview of the use of milk thistle as a treatment and adjunct agent in cancer therapy. The summary includes a brief history of milk thistle,a review of the laboratory studies and clinical trials,and a description of adverse effects associated with milk thistle use. This summary contains the following key ...
Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Non-Small Cell Lung Cancer
Treatment of recurrent non-small cell lung cancer may include the following:External radiation therapy as palliative therapy, to relieve pain and other symptoms and improve the quality of life.Chemotherapy.Targeted therapy with a tyrosine kinase inhibitor.Laser therapy or internal radiation therapy using an endoscope.Radiosurgery (for certain patients who cannot have surgery).Surgery to remove a very small amount of cancer that has spread to the brain.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent non-small cell lung cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Pediatric Supportive Care (PDQ®): Supportive care - Patient Information [NCI] - End-of-Life Care
Parents are partners with doctors in decisions about their child's end-of-life care.Even though new and better treatments have increased the chances of a cure or remission, some types of childhood cancer do not get better. When a child's cancer does not get better or comes back, parents may not be sure about whether to continue treatment and, if so, what kind. Parents who are caring for a child at the end of life need a lot of support that includes family members and the child's health care team. The health care team can help parents understand how different types of treatment can affect their child's quality of life. Parents have to decide if they want their child to continue to receive treatment even if it is not likely to affect the cancer. They also have to decide if they want their child to take part in decisions about end-of-life care.Parents have reported that they find the most support from cancer treatment doctors who:Give clear information.Communicate in a caring and
Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityThere are three main types of skin cancer:Basal cell carcinoma (BCC).Squamous cell carcinoma (SCC), which together with BCC is referred to as nonmelanoma skin cancer (NMSC).Melanoma.BCC and SCC are the most common forms of skin cancer but have substantially better prognoses than the less common, generally more aggressive, melanoma.NMSC is the most commonly occurring cancer in the United States. Its incidence appears to be increasing in some, but not all, areas of the country. Overall U.S. incidence rates have likely been increasing for a number of years. At least some of this increase may be attributable to increasing skin cancer awareness and resulting increasing investigation and biopsy of skin lesions. The total number and incidence rate of NMSCs cannot be estimated precisely because reporting to cancer registries is not required. However, based on extrapolation of Medicare fee-for-service data to the U.S.